Palvella Therapeutics share#snapshot#suffix 140764982 / US6979471090
138.93
USD
7.43
USD
5.65 %
09.10.2026
BTT
| prices + charts + realtime | news + analysis | fundamental | company | corresponding shares | action | |
|---|---|---|---|---|---|---|
| price + Chart | chart (large) | news + ad-hoc | balance sheet/p&l | fixed dates | certificates | portfolio#add_instrument_to#depot |
| times + sale | chart comparison | analysis | detailnavigation#shares#estimates | profile | portfolio#add_instrument_to#watchlist | |
| stock exchange | realtime push | stock price appreciation potential | dividend/annual shareholders' meeting | |||
| historic | analysis | |||||
prices + charts + realtime
news + analysis
fundamental
company
corresponding shares
Aktie Analysen & Prognosen
Fundamentalanalyse
| Preis | Mrk. Kap. in Mrd. $ | revid. Gew. Prognose | Bewertung | Wachstum / KGV | KGV 2020 | langfrist. Wachstum | Div. Rend. | mittelfrist. Mkt Trend | rel. 4 Wo. Perform. |
|---|---|---|---|---|---|---|---|---|---|
| 138.77 USD | % | % | % |
| revid. Gewinn Prognose | ||||
| Bewertung | ||||
| relative 4 Wochen Performance | % | |||
| mittelfristiger Markttrend | ||||
| Markt Kapitalisierung in Mrd. $ | Grosser Marktwert | Mit einer Marktkapitalisierung von > $5 Mrd., ist ein hoch kapitalisierter Titel. | ||
| Wachstum / KGV | ||||
| KGV | ||||
| langfristiges Wachstum | % | Wachstum heute bis p.a. | Die durschnittlichen jährlichen Wachstumsraten gelten für die Gewinne von heute bis | |
| Anzahl der Analysten | Nur von wenigen Analysten verfolgt | In den zuräckliegenden sieben Wochen haben durchschnittlich Analysten eine Schätzung des Gewinns pro Aktie für diesen Titel abgegeben. | ||
| Dividenden Rendite | % | |||
| Zeichenerklärung | ||
|---|---|---|
| revidierte Gewinn Prognose | = , | = , |
| Bewertung | = , | = , , |
| relative 4 Wochen Performance | = negative Werte | = positive Werte |
| mittelfristiger Markttrend | = , | = , |
Risikoanalyse
| Preis | Mrk. Kap. in Mrd. $ | Bear Market Faktor | Bad News Faktor | Beta 1 Jahr | Korrelation |
|---|---|---|---|---|---|
| 138.77 USD |
| Risiko | |||
| Bear Market | |||
| Bad News | |||
| Beta | Die Aktie tendiert dazu, pro 1% Indexbewegung mit einem Ausschlag von % zu reagieren. | ||
| Korrelation 365 Tage | |||
shares#estimates#headline Palvella Therapeutics in USD
| 2026 | 2027 | 2028 | 2029 | 2030 | |
|---|---|---|---|---|---|
| shares#estimates#column#sales | 0.00 | 27.19 | 114.04 | 310.29 | 648.23 |
| shares#estimates#column#dividendspershare | |||||
| shares#estimates#column#dividendyield | % | % | % | % | % |
| shares#estimates#column#earningpersharebasic | -6.60 | -7.98 | -5.77 | 1.94 | 14.30 |
| shares#estimates#column#pricetoearningsratio | -21.02 | -17.38 | -24.04 | 71.46 | 9.70 |
| shares#estimates#column#earningsbeforeinterestandtaxes | -94.76 | -134.35 | -96.77 | 37.05 | 301.14 |
| shares#estimates#column#earningsbeforeinteresttaxesdepreciationamortization | -85.81 | -93.81 | -34.01 | 161.84 | 682.43 |
| shares#estimates#column#netprofit | -95.09 | -132.95 | -95.26 | 34.45 | 266.82 |
| shares#estimates#column#netprofitadjusted | -92.37 | -113.25 | -64.85 | 75.61 | 376.83 |
| shares#estimates#column#pretaxprofit | -96.46 | -136.66 | -105.50 | 27.26 | 286.51 |
| shares#estimates#column#pretaxprofitreported | |||||
| shares#estimates#column#earningpersharenongaap | -6.29 | -7.14 | -4.37 | 5.43 | 27.32 |
| shares#estimates#column#earningpersharereported | -6.02 | -6.43 | -4.54 | 0.52 | 7.12 |
| shares#estimates#column#grossincome | 0.00 | 28.46 | 112.13 | 293.62 | 642.61 |
| shares#estimates#column#cashflowfrominvesting | -85.59 | -0.20 | -0.30 | -0.40 | -0.50 |
| shares#estimates#column#cashflowfromoperations | -76.09 | -108.73 | -112.86 | -26.01 | 105.07 |
| shares#estimates#column#cashflowfromfinancing | 217.29 | 5.12 | 240.12 | 5.12 | 5.12 |
| shares#estimates#column#cashflowpershare | |||||
| shares#estimates#column#freecashflow | |||||
| shares#estimates#column#freecashflowpershare | |||||
| shares#estimates#column#bookvaluepershare | |||||
| shares#estimates#column#netdebt | -190.60 | ||||
| shares#estimates#column#researchanddevelopment | 54.87 | 78.09 | 92.05 | 104.85 | 121.04 |
| shares#estimates#column#capitalexpenditure | 0.10 | 0.20 | 0.30 | 0.40 | 0.50 |
| shares#estimates#column#sellinggeneralandadministrativeexpense | 42.53 | 79.21 | 139.20 | 174.87 | 187.27 |
| shares#estimates#column#shareholdersequity | 160.09 | 54.38 | 214.86 | 231.06 | 358.88 |
| shares#estimates#column#totalassets | 201.90 | 100.26 | 275.32 | 300.53 | 439.30 |
shares#estimates#footer
Palvella Therapeutics Inc Registered shs Aktie Analysen
error#message#nodata